EGFR and neoplasm: The concordance for commonly known activating EGFR mutations was 88 %, indicating better performance for specific clinically relevant mutations, and strongly suggests that cfDNA can assist in treatment decisions of majority cases, where at times the tumor tissue cannot be obtained.